Terex announced that it has agreed to sell its Demag Mobile Cranes business to Tadano Ltd. for an enterprise value of approximately $215M. The Demag Mobile Cranes business manufactures and sells all terrain cranes and large crawler cranes. Included in the transaction are the manufacturing facilities in Zweibrucken, Germany and multiple sales and service locations. The sale, which is subject to government regulatory approvals and other customary closing conditions, is targeted to close in mid-2019.

Canyon Partners issued the following statement regarding Caesars Entertainment: "Canyon has reviewed the recent public statements by certain significant shareholders regarding the strategic direction of the company. In order to ensure the record is clear regarding Canyon's independent opinion on these matters, Canyon's current view is that shareholder value would be best served and enhanced by an open sale process that will be presented to shareholders for a vote thereon."

The dividend will be paid on or about March 29, 2019 to stockholders of record as of the close of business on March 8, 2019.

As previously disclosed, Global Eagle Entertainment Inc. has been implementing an operating expense savings initiative, which includes a global footprint consolidation, simplification of its management structure, IT programs that will increase efficiency and automation, and other operating expense reductions. In connection with this initiative, on February 5, 2019, the company committed to reduce its global workforce by approximately 15% and communicated this determination to its employees on February 20, 2019. The changes to the company's workforce will vary by country, based on legal requirements and required consultations with works councils and other employee representatives, as appropriate. The company estimates that it will incur total expenses relating to the workforce reduction of approximately $4.5M, all of which represents cash expenditures relating to severance and transition-related expenses. Of this total amount, the company expects to record substantially all of it in the first quarter of 2019, with the remainder to follow in the second quarter of 2019 and the balance in the third quarter of 2019.

In a regulatory filing, Northrop Grumman corporate VP of government relations Lesley A. Kalan disclosed the sale of 4,312 common shares of the company at a price of $286.70 per share.

Technical Comm Corp announced that the company received notice from the Nasdaq listing qualifications department of Nasdaq that, because the company had not yet filed its Form 10-Q for the period ended December 29, 2018 and because the company remains delinquent in filing its Form 10-K for the period ended September 29, 2018, the company was not in compliance with Nasdaq continued listing Rule 5250, which rule requires companies with securities listed on Nasdaq to timely file all required periodic reports with the U.S. Securities and Exchange Commission. Pursuant to such notice, the company will have until March 4 to submit a plan to Nasdaq to regain compliance; if the plan is accepted, Nasdaq can grant an exception of up to 180 days from the due date of the filing, or until July 15, to regain compliance. The company's failure to timely file its quarterly report on Form 10-Q for the fiscal quarter ended December 29, 2018 and annual report on Form 10-K for fiscal year ended September 29, 2018 is primarily due to certain changes to the company's revenue recognition which have impacted the filing of its 2018 Form 10-K, Q1 Form 10-Q and related financial statements, and the reliance on certain other previously issued financial statements. The company will complete the required filings as soon as practical after its current and former independent public accounting firms review and complete the audits of such financial statements. TCC is currently working with its current and former independent registered public accounting firms to complete such audits and restatements, and will provide information to Nasdaq in its plan to regain compliance as to the expected filing date of the annual report, although at this time the company does not have an estimate as to the date such filing will be made.

InfuSystem Holdings announced that on December 7, 2018, it entered into a Stipulation and Agreement of Settlement in the shareholder derivative action captioned Thomas v. Steen, Case No. BC656147, pending in the Superior Court of California for the County of Los Angeles. The Stipulation of Settlement calls for the company to adopt certain corporate governance changes. On February 4, the Court entered an order providing for preliminary approval of the Settlement and the Notice to Current InfuSystem Stockholders. A final settlement hearing is scheduled for April 19 at 8:30 AM at the Court.

Kaiser Aluminum announced the appointment of Neal E. West as Senior Vice President and Chief Financial and Accounting Officer, effective today. Daniel J. Rinkenberger will serve as an advisor to the company through his planned retirement on March 31, 2019. Mr. West joined the company in 2008 and has served as the Vice President and Chief Accounting Officer since that time.

Alder BioPharmaceuticals announced it has submitted a biologics license application, or BLA, to the FDA for eptinezumab. Eptinezumab is an investigational monoclonal antibody, or mAb, for migraine prevention targeting the calcitonin gene-related peptide, or CGRP, and is Alder's lead commercial candidate. If the BLA submission is accepted and the FDA grants approval of eptinezumab, Alder will be on track for a Q1 2020 commercial launch. Eptinezumab has been evaluated in several global, randomized, double-blind, placebo-controlled studies to assess its safety and efficacy in both chronic and episodic migraine prevention. The BLA includes, and is supported by, positive data from Alder's PROMISE 1 and PROMISE 2 Phase 3 clinical trials, open-label safety study, pharmacokinetic comparability study and chemistry, manufacturing, and controls, or CMC, data packages. Top-line results from the PROMISE 1 and PROMISE 2 Phase 3 clinical trials were presented at the American Association of Neurology and American Headache Society.

Bristol-Myers Squibb Company (BMY) announced that it has filed definitive proxy materials with the SEC in connection with the company's pending merger with Celgene Corporation (CELG). Bristol-Myers Squibb will commence mailing the joint proxy statement / prospectus to its stockholders on or about February 22. The Bristol-Myers Squibb Special Meeting of Stockholders is scheduled to take place on April 12. All stockholders of record of Bristol-Myers Squibb common stock as of the close of business on March 1 will be entitled to vote their shares either in person or by proxy at the stockholder meeting. The Bristol-Myers Squibb board believes this combination is in the best interests of the company and its stockholders, and recommends that stockholders vote "FOR" the approval of the issuance of shares of Bristol-Myers Squibb common stock in the merger, as well as all other proposals included on the enclosed WHITE proxy card. As previously announced on January 3, the combination of Bristol-Myers Squibb and Celgene will create a leading focused specialty biopharma company that is well positioned to address the needs of patients with cancer, inflammatory and immunologic disease and cardiovascular disease through high-value innovative medicines and leading scientific capabilities.